Proteomics in Small Cell Lung Cancer
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Small Cell Lung Cancer. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Denmark
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Circulating Metabolites and Tumor-derived Extravesicular Proteins in Small Cell Lung Cancer
Overview
The aim of this study is to gather insight into tumor-derived circulating extracellular vesicles-proteins in patients with newly diagnosed small cell lung cancer.
Detailed description
The study will include 50 patients with newly diagnosed SCLC, referred to systemic antineoplastic treatment at the Dept. of Oncology, Aalborg University Hospital and blood samples from 50 healthy blood donors.
The blood samples from SCLC patients will be collected before chemotherapy with Carboplatin and Etoposide and after 2 cycles of chemotherapy.
Imaging will be performed at the Dept. of Radiology, Aalborg University Hospital before chemotherapy and after 3 cycles of the treatment.
Primary outcome measures
- Identification and validation of protein biomarkers [Time frame: 3 years]
Eligibility criteria
Inclusion criteria
- Written and signed informed consent
- Histopathologically and/or cytologically newly-diagnosed SCLC
- Measurable disease on CT scans
- Eligibility to receive standard chemotherapy consisting of carboplatin and etoposide
Exclusion criteria
- Active biopsy-verified second malignancy other than non-melanoma skin cancer or cervical carcinoma in situ
- Prior treatment for any malignant diseases other than non-melanoma skin cancer and cervical carcinoma in situ
- Concomitant anticoagulation treatment (acetylsalicylic acid and clopidogrel are allowed)
- Treatment with any other investigational agent
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Case-control
Study locations
Denmark · 1 center
- Aalborg University Hospital — Aalborg
Identifiers
NCT: NCT05623956 · N-20220023